Information Provided By:
Fly News Breaks for May 31, 2016
CPXX, JAZZ
May 31, 2016 | 10:15 EDT
Wells Fargo analyst David Maris says that while Jazz Pharmaceuticals (JAZZ) paid a "large" premium for Celator Pharmaceuticals (CPXX), the deal provides a "strong strategic fit" for the company. The analyst believes Jazz still has capacity for further strategic growth through acquisitions. He keeps an Outperform rating on the shares with a $173-$177 price target range.
News For JAZZ;CPXX From the Last 2 Days
There are no results for your query JAZZ;CPXX